Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Anokion is an innovative immune tolerance company focused on providing a more effective approach to treating autoimmune diseases. Their proprietary immune tolerance platform features proteins engineered to deliver precise, targeted disease therapy without the side effects of broad immunosuppression. By specifically targeting autoreactive cells for removal while leaving healthy immune cells untouched, Anokion's approach aims to transform treatment for autoimmune patients worldwide. Founded in Switzerland and based on innovation from EPFL Life Sciences, Anokion is led by a diverse team of entrepreneurial scientists and experienced industry professionals.
Sebastian Maerkl, Fabien Louis Claude Robert Jammes